British Biotech Reports Share Purchases by Senior Executives.Business Editors OXFORD, United Kingdom--(BUSINESS WIRE)--Jan. 7, 2003 British Biotech British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] plc (LSE LSE - Language Sensitive Editor : BBG BBG Brooklyn Botanic Garden BBG Broadcasting Board of Governors BBG Bloomberg (financial company) BBG Bundesbeamtengesetz (German Law) BBG Bergbau-Berufsgenossenschaft (Germany) , NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BBIOD) today announced public filings that report significant purchases of ordinary shares by the Company's Chairman, acting Chief Executive Officer and Finance Director, each of whom is a director of the Company. In a report filed with the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. , the Company reported the purchase on January 6, 2003, of 1,000,000 million ordinary shares by Chairman Dr Peter Fellner at a price of 3.5 pence per share; of 1,188,064 ordinary shares by acting Chief Executive Officer Timothy Edwards at 4 pence per share; and of 928,170 ordinary shares by Tony Weir, Finance Director at 4 pence per share. This news release contains forward-looking statements that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process. British Biotech plc British Biotech is a research and development stage company aiming to develop and commercialise specialist drugs for serious illnesses. It currently has four products in early clinical studies, supplemented by focused drug discovery research programmes. These are in the fields of inflammatory disease Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; , in collaboration with Serono; and bacterial infections, in collaboration with GeneSoft. British Biotech currently has 86 employees, and had (pounds)42.8 million cash and liquid resources at October 31, 2002. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion